Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CVKD
CVKD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CVKD News
Cadrenal Therapeutics Reports FY Losses
4d ago
seekingalpha
Cadrenal Reports 2025 Financials and CAD-1005 Progress Update
4d ago
Newsfilter
Life Sciences Virtual Investor Forum Highlights Available On-Demand
Mar 13 2026
Globenewswire
Life Sciences Virtual Investor Forum Agenda Announced
Mar 10 2026
Globenewswire
CAD-1005 Phase 2 Trial Shows Significant Reduction in Thrombotic Events
Feb 24 2026
Newsfilter
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial
Jan 20 2026
stocktwits
Cadrenal Acquires VLX-1005 to Strengthen Anticoagulation Pipeline
Dec 11 2025
Globenewswire
Cadrenal Acquires VLX-1005, Strengthening Anticoagulation Pipeline
Dec 11 2025
Newsfilter
Cadrenal Therapeutics Appoints Dr. Lee Scott Golden to Board, Enhancing Anticoagulation Development
Dec 01 2025
Newsfilter
Cadrenal Therapeutics, LLC
Nov 08 2025
NASDAQ.COM
Cadrenal Therapeutics to Attend Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Sep 29 2025
Newsfilter
Cadrenal Therapeutics Expands Anticoagulation Pipeline by Acquiring eXIthera's Factor XIa Inhibitor Portfolio
Sep 15 2025
Newsfilter
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 11 2025
Newsfilter
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
Aug 05 2025
Newsfilter
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
Jun 12 2025
Newsfilter
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
Jun 04 2025
Newsfilter
Show More News
